Baxter International (NYSE:BAX) Price Target Raised to $25.00

Baxter International (NYSE:BAX) had its price target lifted by research analysts at Wells Fargo & Company from $23.00 to $25.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 10.89% from the company’s previous close.

Several other brokerages also recently weighed in on BAX. The Goldman Sachs Group upped their target price on shares of Baxter International from $19.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Wolfe Research initiated coverage on Baxter International in a report on Tuesday, October 20th. They issued a “peer perform” rating on the stock. Barclays assumed coverage on shares of Baxter International in a research report on Wednesday, October 7th. They set an “underweight” rating and a $20.00 target price for the company. Stifel Nicolaus increased their price objective on shares of Baxter International from $19.00 to $24.00 and gave the company a “hold” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings cut Baxter International from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $22.45.

Baxter International Stock Performance

Shares of BAX stock traded down $0.96 during trading hours on Friday, reaching $22.54. 5,867,234 shares of the company traded hands, compared to its average volume of 7,808,448. The firm has a 50-day moving average price of $24.65 and a 200 day moving average price of $21.35. The company has a market cap of $11.66 billion, a P/E ratio of -10.89, a P/E/G ratio of 3.85 and a beta of 0.65. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. Baxter International has a 12-month low of $15.73 and a 12-month high of $30.00.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. The company had revenue of $2.98 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.69 EPS. As a group, sell-side analysts predict that Baxter International will post 2.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Baxter International

A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Baxter International in the second quarter worth $1,744,874,000. Pzena Investment Management LLC bought a new stake in shares of Baxter International during the second quarter worth $1,392,098,000. Equity Investment Corp purchased a new stake in shares of Baxter International during the second quarter valued at $146,815,000. Bank of America Corp DE bought a new position in shares of Baxter International in the second quarter worth about $132,993,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Baxter International in the second quarter worth about $68,036,000. 90.19% of the stock is owned by institutional investors.

Trending Headlines about Baxter International

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter reported third-quarter adjusted earnings of $0.58 per share and revenue of $2.98 billion, exceeding analyst estimates of $0.52 and $2.91 billion, respectively. Revenue increased 5% year over year, supported by broad-based segment growth. Baxter International Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management raised its full-year 2026 earnings outlook, signaling confidence in demand and operating performance. The guidance increase is supportive for the stock, although ongoing margin pressure remains a concern. Baxter Raises 2026 Earnings Guidance
• Neutral Sentiment: Baxter declared a quarterly dividend of $0.01 per share, payable January 4 to shareholders of record November 27. The annualized yield is approximately 0.2%, so the payment provides limited income support for investors. Baxter Raises Guidance and Declares Dividend
• Negative Sentiment: The company received an FDA warning letter citing cGMP violations. The notice could increase compliance costs, require remediation, and create risks to manufacturing or product approvals, potentially offsetting the benefit of the earnings beat and higher guidance. Baxter Received FDA Warning Letter Over cGMP Violations

About Baxter International

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.